

CITATION REPORT

List of articles citing

A highly selective and specific PET tracer for imaging of tau pathologies

DOI: 10.3233/jad-2012-120712

Journal of Alzheimer's Disease, 2012, 31, 601-12.

Source: <https://exaly.com/paper-pdf/53098260/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
156	Neuroimaging insights into network-based neurodegeneration. 2012 , 25, 727-34		52
155	Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. 2012 , 3, 936-41		46
154	Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and Amyloid plaques in Alzheimer's disease models. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 9170-80	8.3	58
153	Development of positron emission tomography Amyloid plaque imaging agents. <i>Seminars in Nuclear Medicine</i> , 2012 , 42, 423-32	5.4	132
152	Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. 2013 , 79, 1094-108		556
151	Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of pathology. 2013 , 4, 852		21
150	The first synthesis of [11C]J147, a new potential PET agent for imaging of Alzheimer's disease. 2013 , 23, 524-7		4
149	Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 457-68	4.3	511
148	Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. <i>Journal of Alzheimer's Disease</i> , 2013 , 34, 1-114	4.3	15
147	PET scanning of brain tau in retired national football league players: preliminary findings. 2013 , 21, 138-44		154
146	[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. 2013 , 9, 666-76		421
145	Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. 2013 , 9, 192-200		197
144	Alzheimer disease: [11C]PBB3--a new PET ligand that identifies tau pathology in the brains of patients with AD. 2013 , 9, 599		26
143	Developing Targeted PET Tracers in the Era of Personalized Medicine. 2013 , 289-342		
142	Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1420-7	8.9	223
141	Design, synthesis and biological evaluation of trimethine cyanine dyes as fluorescent probes for the detection of tau fibrils in Alzheimer's disease brain and olfactory epithelium. 2013 , 8, 891-7		22
140	A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. 2013 , 56, 736-40		63

139	Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. 2014 , 95, 67-77		17
138	Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , 2013 , 36, 311-20	4.3	17
137	Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. 2014 , 4,		11
136	Antibody-derived in vivo imaging of tau pathology. 2014 , 34, 16835-50		42
135	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. 2014 , 9, 597-613		2
134	Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. 2014 , 57, 18-24		27
133	Reporters of Amyloid Structural Polymorphism. 2014 , 69-79		1
132	Developments in Tau PET Imaging. 2014 , 41, 547-53		40
131	Tau immunotherapy and imaging. 2014 , 13, 103-6		19
130	The neuropathology of sport. 2014 , 127, 29-51		258
129	Biomarker modelling of early molecular changes in Alzheimer's disease. 2014 , 18, 213-27		4
128	Concise and high-yield synthesis of T808 and T808P for radiosynthesis of [(18)F]-T808, a PET tau tracer for Alzheimer's disease. 2014 , 24, 254-7		20
127	The evolution of preclinical Alzheimer's disease: implications for prevention trials. 2014 , 84, 608-22		429
126	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. 2014 , 37, 629-41		32
125	Alzheimer's disease, anesthesia, and surgery: a clinically focused review. 2014 , 28, 1609-23		32
124	Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 871-4	8.9	57
123	Synthesis and evaluation of (13)N-labelled azo compounds for Amyloid imaging in mice. 2014 , 16, 538-49		14
122	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. 2014 , 6, 1		110

121	Neuroimaging in repetitive brain trauma. 2014 , 6, 10		38
120	Biomarkers in dementia: clinical utility and new directions. 2014 , 85, 1426-34		98
119	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 816-26	8.8	137
118	Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. <i>Current Neurology and Neuroscience Reports</i> , 2014 , 14, 472	6.6	33
117	One-pot synthesis of benzo[4,5]imidazo[1,2-a]quinazoline derivatives via facile transition-metal-free tandem process. 2014 , 16, 328-32		25
116	High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. <i>ACS Chemical Neuroscience</i> , 2014 , 5, 718-30	5.7	64
115	In vivo tau imaging: obstacles and progress. 2014 , 10, S254-64		75
114	[Interest and role of brain scintigraphy in the diagnosis of dementia in 2014]. 2014 , 12, 413-23		
113	Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. <i>Journal of Alzheimer's Disease</i> , 2014 , 42 Suppl 4, S421-9	4.3	60
112	Harnessing the immune system for treatment and detection of tau pathology. <i>Journal of Alzheimer's Disease</i> , 2014 , 40 Suppl 1, S113-21	4.3	17
111	The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using (18)F-AV45: Is Amyloid the Principal Actor in the Disease?. 2014 , 4, 431-41		7
110	Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model. 2015 , 5, 15703		19
109	A review of neuroimaging findings in repetitive brain trauma. 2015 , 25, 318-49		80
108	Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. 2015 , 78, 787-800		448
107	Neuroimaging assessment of early and late neurobiological sequelae of traumatic brain injury: implications for CTE. <i>Frontiers in Neuroscience</i> , 2015 , 9, 334	5.1	32
106	Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. <i>Frontiers in Neuroscience</i> , 2015 , 9, 482	5.1	17
105	Novel PET/SPECT probes for imaging of tau in Alzheimer's disease. 2015 , 2015, 124192		14
104	Fully automated synthesis of [(18)F]T807, a PET tau tracer for Alzheimer's disease. 2015 , 25, 2953-7		22

103	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 4365-82	8.3	77
102	Spreading of pathology in neurodegenerative diseases: a focus on human studies. 2015 , 16, 109-20		484
101	Organofluorine Compounds as Positron Emission Tomography Tracers. 2015 , 201-240		1
100	General Aspects of Organofluorine Compounds. 2015 , 1-27		5
99	A critical review of chronic traumatic encephalopathy. 2015 , 56, 276-93		82
98	Diagnostica per immagini cerebrale tramite tomografia a emissione di positroni in neurologia: dalla misurazione del flusso sanguigno e del metabolismo all' esplorazione della neurotrasmissione. 2015 , 15, 1-9		
97	Chronic traumatic encephalopathy: contributions from the Boston University Center for the Study of Traumatic Encephalopathy. 2015 , 29, 154-63		23
96	Tau immunotherapy for Alzheimer's disease. 2015 , 21, 394-402		192
95	Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer's disease. 2015 , 25, 4587-92		24
94	Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7241-57	8.3	36
93	PET Radioligands for Imaging of Tau Pathology: Current Status. <i>Nuclear Medicine and Molecular Imaging</i> , 2015 , 49, 251-7	1.9	9
92	Tau imaging: early progress and future directions. 2015 , 14, 114-24		360
91	Invited review: Prion-like transmission and spreading of tau pathology. 2015 , 41, 47-58		100
90	Imaging Alzheimer's disease pathophysiology with PET. 2016 , 10, 79-90		21
89	Insight into the Molecular Imaging of Alzheimer's Disease. 2016 , 2016, 7462014		12
88	Characteristics of Tau and Its Ligands in PET Imaging. 2016 , 6, 7		71
87	Optimization and Biodistribution of [(11)C]-TKF, An Analog of Tau Protein Imaging Agent [(18)F]-THK523. <i>Molecules</i> , 2016 , 21,	4.8	2
86	Synthesis of Naphthalene-Based Push-Pull Molecules with a Heteroaromatic Electron Acceptor. <i>Molecules</i> , 2016 , 21, 267	4.8	9

85	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. 2016 , 7, 88		20
84	Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807. 2016 , 15,		33
83	Sports-related brain injuries: connecting pathology to diagnosis. 2016 , 40, E14		18
82	Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain. <i>ACS Chemical Neuroscience</i> , 2016 , 7, 897-911	5.7	17
81	Genetics of Frontotemporal Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2016 , 16, 107	6.6	72
80	Characterization of the radiolabeled metabolite of tau PET tracer F-THK5351. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 2211-2218	8.8	15
79	Tau imaging in neurodegenerative diseases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1139-50	8.8	89
78	Preclinical Evaluation of [(18F)THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. 2016 , 18, 258-66		23
77	Tau PET imaging: present and future directions. 2017 , 12, 19		172
76	cGMP production of the radiopharmaceutical [F]MK-6240 for PET imaging of human neurofibrillary tangles. 2017 , 60, 263-269		17
75	PET Imaging Agents for Alzheimer's Disease. 2017 , 181-197		
74	Alzheimer's Disease II. 2017 ,		2
73	Tau Positron Emission Tomography Imaging. 2017 , 9,		15
72	Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules. 2017 , 7,		10
71	The Prion-Like Behavior of Assembled Tau in Transgenic Mice. 2017 , 7,		22
70	Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 527-536	4.3	0
69	Advanced Drug Discovery for Alzheimer's Disease: Challenges and Strategies. 2017 , 9-29		
68	Synthesis of Thiophene-Based Optical Ligands That Selectively Detect Tau Pathology in Alzheimer's Disease. <i>Chemistry - A European Journal</i> , 2017 , 23, 17127-17135	4.8	19

67	Drug Design: Principles and Applications. 2017 ,		3
66	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 7350-7370	8.3	51
65	A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [F]-THK-5351. 2017 , 60, 140-146		2
64	Alzheimer's Disease. 2017 , 83-118		1
63	Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 484-491	8.9	65
62	Chronic traumatic encephalopathy. 400-414		0
61	Tau Imaging for a Diagnostic Platform of Tauopathy Using the rTg4510 Mouse Line. 2017 , 8, 663		7
60	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. 2017 , 9, 96		65
59	From Imaging Agents to Theranostic Drugs in Alzheimer's Disease. 2017 , 74-106		
58	Triphenylphosphine/Isocyanide Mediated Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidine, Enamine Ketones and Secondary Ketimines. 2018 , 3, 946-950		1
57	An Aspartyl Cathepsin Targeted PET Agent: Application in an Alzheimer's Disease Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 1241-1252	4.3	5
56	Lewis-acid Promoted Chemoselective Condensation of 2-Aminobenzimidazoles or 3-Aminoindazoles with 3-Ethoxycyclobutanones to Construct Fused Nitrogen heterocycles. <i>Advanced Synthesis and Catalysis</i> , 2018 , 360, 1943-1948	5.6	28
55	Detection and Imaging of A β -42 and Tau Fibrils by Redesigned Fluorescent X-34 Analogues. <i>Chemistry - A European Journal</i> , 2018 , 24, 7210-7216	4.8	13
54	Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. <i>Nuclear Medicine and Molecular Imaging</i> , 2018 , 52, 24-30	1.9	9
53	Fluorine-19 magnetic resonance imaging probe for the detection of tau pathology in female rTg4510 mice. <i>Journal of Neuroscience Research</i> , 2018 , 96, 841-851	4.4	6
52	Preclinical Evaluation of F-RO6958948, C-RO6931643, and C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 675-681	8.9	49
51	Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018 , 39, 691-708	5.9	36
50	Imaging Protein Misfolding in the Brain Using β Sheet Ligands. <i>Frontiers in Neuroscience</i> , 2018 , 12, 585	5.1	21

49	PET/CT of Dementia. <i>American Journal of Roentgenology</i> , 2018 , 211, 246-259	5.4	11
48	A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease. <i>GigaScience</i> , 2018 , 7,	7.6	3
47	Novel D-A-D based near-infrared probes for the detection of Amyloid and Tau fibrils in Alzheimer's disease. <i>Chemical Communications</i> , 2018 , 54, 8717-8720	5.8	27
46	Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 34	7.3	20
45	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	28
44	Neuronal levels and sequence of tau modulate the power of brain rhythms. <i>Neurobiology of Disease</i> , 2018 , 117, 181-188	7.5	24
43	Microglial Activation During Pathogenesis of Tauopathy in rTg4510 Mice: Implications for the Early Diagnosis of Tauopathy. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S353-S359	4.3	8
42	An one-pot two-step automated synthesis of [18F]T807 injection, its biodistribution in mice and monkeys, and a preliminary study in humans. <i>PLoS ONE</i> , 2019 , 14, e0217384	3.7	2
41	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. <i>Human Brain Mapping</i> , 2019 , 40, 5424-5442	5.9	57
40	AD molecular: Imaging tau aggregates with positron emissions tomography. <i>Progress in Molecular Biology and Translational Science</i> , 2019 , 165, 107-138	4	7
39	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. <i>Progress in Molecular Biology and Translational Science</i> , 2019 , 165, 63-106	4	4
38	Synthesis and bioevaluation of technetium-99 m / rhenium labeled phenylquinoxaline derivatives as Tau imaging probes. <i>European Journal of Medicinal Chemistry</i> , 2019 , 177, 291-301	6.8	2
37	Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. <i>Current Neurology and Neuroscience Reports</i> , 2019 , 19, 45	6.6	34
36	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1128, 45-83	3.6	21
35	Phosphoramidates as Steering Elements for Highly Selective Access to Complementary Imidazo[1,2-]pyrimidine Isomers. <i>Organic Letters</i> , 2019 , 21, 9527-9531	6.2	7
34	Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience. <i>Frontiers in Medicine</i> , 2019 , 6, 268	4.9	6
33	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 451-489	8.8	50
32	Coevolution of Atomic Resolution and Whole-Brain Imaging for Tau Neurofibrillary Tangles. <i>ACS Chemical Neuroscience</i> , 2020 , 11, 2513-2522	5.7	5

31	DMAP-Catalyzed C-N Bond Formation for Diverse Synthesis of Imidazo[1,2-a]pyrimidine and Pyrimido[1,2-a]benzimidazole Derivatives. <i>Chinese Journal of Chemistry</i> , 2020 , 38, 1595-1599	4.9	1
30	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. <i>Brain</i> , 2020 , 143, 1010-1026	11.2	35
29	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. <i>Molecules</i> , 2020 , 25,	4.8	30
28	Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2021 , 430, 213659	23.2	4
27	Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents. <i>Molecular Pharmaceutics</i> , 2021 , 18, 1176-1195	5.6	4
26	Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. <i>Neuroscientist</i> , 2021 , 1073858421997035	8.5	35
25	PET Agents in Dementia: An Overview. <i>Seminars in Nuclear Medicine</i> , 2021 , 51, 196-229	5.4	10
24	Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2021 , 96-97, 112-147	2.1	1
23	Review Electrochemical Strategies for Selective Fluorination of Organic Compounds. <i>Journal of the Electrochemical Society</i> , 2021 , 168, 075503	3.9	3
22	[C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 12003-12021	8.3	4
21	A biophysical model of shape changes due to atrophy in the brain with Alzheimer's disease. <i>Lecture Notes in Computer Science</i> , 2014 , 17, 41-8	0.9	2
20	Tau PET Imaging. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1184, 217-230	3.6	4
19	Tau Protein Binding Modes in Alzheimer's Disease for Cationic Luminescent Ligands. <i>Journal of Physical Chemistry B</i> , 2021 , 125, 11628-11636	3.4	0
18	Introduction. <i>Springer Theses</i> , 2017 , 1-24	0.1	
17	Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.		2
16	H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults.. <i>Neurobiology of Aging</i> , 2022 , 112, 16-26	5.6	2
15	Recent development in selective Tau tracers for PET imaging in the brain. <i>Chinese Chemical Letters</i> , 2022 ,	8.1	0
14	Drug delivery of memantine with carbon dots for Alzheimer's disease: blood-brain barrier penetration and inhibition of tau aggregation.. <i>Journal of Colloid and Interface Science</i> , 2022 , 617, 20-31	9.3	2

13	Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	4
12	Benzo[4,5]imidazo[1,2-a]pyridines and benzo[4,5]imidazo[1,2-a]pyrimidines: Recent advancements in synthesis of two diversely important heterocyclic motifs and their derivatives. <i>New Journal of Chemistry</i> ,	3.6	0
11	Molecular PET Imaging in Alzheimer's Disease. <i>Journal of Medical and Biological Engineering</i> ,	2.2	0
10	CHAPTER 9. Fluorine in Medicine. 2022 , 440-458		
9	Quantifying Water Provision Service Supply, Demand, and Spatial Flow in the Yellow River Basin. 2022 , 14, 10093		0
8	Densité des dépôts de la protéine Tau versus activité métabolique cortico-cérébrale chez des patients atteints de maladie d'Alzheimer ou de pathologies apparentées. 2022 , 46, 183-190		
7	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. 2022 ,		1
6	Discovery and evaluation of aza-fused tricyclic derivatives for detection of Tau pathology in Alzheimer's disease. 2023 , 246, 114991		0
5	Applications of Carbon Dots for the Treatment of Alzheimer's Disease. Volume 17, 6621-6638		0
4	The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET. 2023 , 13, 290		1
3	Evaluation of advanced, pathophysiologic new targets for imaging of CNS.		0
2	Thiophene-based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic Disease Associated Protein Aggregates.		0
1	Molecular Imaging in Neurology. 2023 , 375-423		0